Theriva Biologics, Inc. 8-K Filing
Ticker: TOVX · Form: 8-K · Filed: Nov 12, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Theriva Biologics, Inc. (ticker: TOVX) to the SEC on Nov 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (registered Common stock, par value $0.001 per share TOVX NYSE American Indica).
How long is this filing?
Theriva Biologics, Inc.'s 8-K filing is 2 pages with approximately 581 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-11-12 08:10:35
Key Financial Figures
- $0.001 — registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2530928d1_8k.htm (8-K) — 27KB
- tm2530928d1_ex99-1.htm (EX-99.1) — 114KB
- tm2530928d1_ex99-1img01.jpg (GRAPHIC) — 6KB
- 0001104659-25-109821.txt ( ) — 325KB
- syn-20251112.xsd (EX-101.SCH) — 3KB
- syn-20251112_lab.xml (EX-101.LAB) — 33KB
- syn-20251112_pre.xml (EX-101.PRE) — 22KB
- tm2530928d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On November 12, 2025, Theriva Biologics, Inc., a Nevada corporation (the "Company") issued a press release that included financial information for its quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated November 12, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 12, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer